Development and validation of a new disease activity index as a numerical sum of four variables in patients with early arthritis

Arthritis Care and Research

Volumn 65, Issue 4, 2013, Pages 518-525

  Castrejõn, Isabel ^a,e   Carmona, Loreto ^b   Ortiz, Ana M ^a   Belmonte, Miguel A ^c   Martínez Lõpez, Juan A ^d   González Álvaro, Isidoro ^a  

^a HOSPITAL UNIVERSITARIO DE LA PRINCESA   (Spain)

^b CAMILO JOSÉ CELA UNIVERSITY   (Spain)

^c HOSPITAL GENERAL DE CASTELLÓN   (Spain)

^d Hospital UniversitarioFundación Jiménez Díaz   (Spain)

^e NYU HOSPITAL FOR JOINT DISEASES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

C REACTIVE PROTEIN;

ADULT; ARTHRITIS; ARTICLE; DISEASE ACTIVITY; DISEASE ACTIVITY SCORE; ERYTHROCYTE SEDIMENTATION RATE; FEMALE; HEALTH ASSESSMENT QUESTIONNAIRE; HUMAN; MAJOR CLINICAL STUDY; MALE; PATIENT ASSESSMENT; RHEUMATOID ARTHRITIS; VALIDATION PROCESS;

ADULT; ARTHRITIS, RHEUMATOID; FEMALE; HEALTH STATUS; HUMANS; MALE; REPRODUCIBILITY OF RESULTS; ROC CURVE; SEVERITY OF ILLNESS INDEX; STATISTICS, NONPARAMETRIC;

EID: 84875712392     PISSN: 2151464X     EISSN: 21514658     Source Type: Journal    
DOI: 10.1002/acr.21854     Document Type: Article

References (39)

1. Grigor C, Capell H, Stirling A, McMahon AD, Lock P, Vallance R, et al. Effect of a treatment strategy of tight control for rheumatoid arthritis (the TICORA study): a single-blind randomised controlled trial. Lancet 2004; 364: 263-9.
2. Gonzalez-Alvaro I, Descalzo MA, Carmona L,. Trends towards an improved disease state in rheumatoid arthritis over time: influence of new therapies and changes in management approach. Analysis of the EMECAR cohort. Arthritis Res Ther 2008; 10: R138.
3. Descalzo MA, Carbonell J, Gonzalez-Alvaro I, Sanmarti R, Balsa A, Hernandez-Barrera V, et al, on behalf of the SERAP and PROAR Study Groups. Effectiveness of a clinical practice intervention in early rheumatoid arthritis. Arthritis Care Res (Hoboken) 2012; 64: 321-30.
4. Sokka T, Pincus T,. A historical perspective concerning population-based and clinical studies of early arthritis and early rheumatoid arthritis. Clin Exp Rheumatol 2003; 21: S5-14.
5. Combe B, Benessiano J, Berenbaum F, Cantagrel A, Daures JP, Dougados M, et al. The ESPOIR cohort: a ten-year follow-up of early arthritis in France. Methodology and baseline characteristics of the 813 included patients. Joint Bone Spine 2007; 74: 440-5.
6. De Rooy DP, van der Linden MP, Knevel R, Huizinga TW, van der Helm-van Mil AH,. Predicting arthritis outcomes: what can be learned from the Leiden Early Arthritis Clinic? Rheumatology (Oxford) 2011; 50: 93-100.
7. Smolen JS, Aletaha D, Bijlsma JW, Breedveld FC, Boumpas D, Burmester G, et al. Treating rheumatoid arthritis to target: recommendations of an international task force. Ann Rheum Dis 2010; 69: 631-7.
8. Haraoui B, Smolen JS, Aletaha D, Breedveld FC, Burmester G, Codreanu C, et al. Treating rheumatoid arthritis to target: multinational recommendations assessment questionnaire. Ann Rheum Dis 2011; 70: 1999-2002.
9. Van der Heijde DM, van't Hof MA, van Riel PL, Theunisse LA, Lubberts EW, van Leeuwen MA, et al. Judging disease activity in clinical practice in rheumatoid arthritis: first step in the development of a disease activity score. Ann Rheum Dis 1990; 49: 916-20.
10. Van Gestel AM, Haagsma CJ, van Riel PL,. Validation of rheumatoid arthritis improvement criteria that include simplified joint counts. Arthritis Rheum 1998; 41: 1845-50.
11. Wells G, Becker JC, Teng J, Dougados M, Schiff M, Smolen J, et al. Validation of the 28-joint Disease Activity Score (DAS28) and European League Against Rheumatism response criteria based on C-reactive protein against disease progression in patients with rheumatoid arthritis, and comparison with the DAS28 based on erythrocyte sedimentation rate. Ann Rheum Dis 2009; 68: 954-60.
12. Ahlmen M, Svensson B, Albertsson K, Forslind K, Hafstrom I,. Influence of gender on assessments of disease activity and function in early rheumatoid arthritis in relation to radiographic joint damage. Ann Rheum Dis 2010; 69: 230-3.
13. Sokka T, Toloza S, Cutolo M, Kautiainen H, Makinen H, Gogus F, et al. Women, men, and rheumatoid arthritis: analyses of disease activity, disease characteristics, and treatments in the QUEST-RA study. Arthritis Res Ther 2009; 11: R7.
14. Castrejon Fernandez I, Martinez-Lopez JA, Ortiz Garcia AM, Carmona Ortells L, Garcia-Vicuna R, Gonzalez-Alvaro I,. Influence of gender on treatment response in a cohort of patients with early rheumatoid arthritis in the area 2 of Madrid. Reumatol Clin 2010; 6: 134-40.
15. Unruh AM,. Gender variations in clinical pain experience. Pain 1996; 65: 123-67.
16. Kushner I,. C-reactive protein in rheumatology. Arthritis Rheum 1991; 34: 1065-8.
17. Castrejon I, Ortiz AM, Garcia-Vicuna R, Lopez-Bote JP, Humbria A, Carmona L, et al. Are the C-reactive protein values and erythrocyte sedimentation rate equivalent when estimating the 28-joint disease activity score in rheumatoid arthritis? Clin Exp Rheumatol 2008; 26: 769-75.
18. Smolen JS, Breedveld FC, Schiff MH, Kalden JR, Emery P, Eberl G, et al. A simplified disease activity index for rheumatoid arthritis for use in clinical practice. Rheumatology (Oxford) 2003; 42: 244-57.
19. Aletaha D, Smolen J,. The Simplified Disease Activity Index (SDAI) and the Clinical Disease Activity Index (CDAI): a review of their usefulness and validity in rheumatoid arthritis. Clin Exp Rheumatol 2005; 23: S100-8.
20. Leeb BF, Andel I, Sautner J, Bogdan M, Maktari A, Nothnagl T, et al. Disease activity measurement of rheumatoid arthritis: comparison of the simplified disease activity index (SDAI) and the disease activity score including 28 joints (DAS28) in daily routine. Arthritis Rheum 2005; 53: 56-60.
21. Arnett FC, Edworthy SM, Bloch DA, McShane DJ, Fries JF, Cooper NS, et al. The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum 1988; 31: 315-24.
22. Esteve-Vives J, Batlle-Gualda E, Reig A,. Spanish version of the Health Assessment Questionnaire: reliability, validity and transcultural equivalency. Grupo para la Adaptacion del HAQ a la Poblacion Espanola. J Rheumatol 1993; 20: 2116-22.
23. Tugwell P, Boers M,. Developing consensus on preliminary core efficacy endpoints for rheumatoid arthritis clinical trials: OMERACT Committee. J Rheumatol 1993; 20: 555-6.
24. Tugwell P, Boers M,. OMERACT conference on outcome measures in rheumatoid arthritis clinical trials: introduction. J Rheumatol 1993; 20: 528-30.
25. Prevoo ML, van't Hof MA, Kuper HH, van Leeuwen MA, van de Putte LB, van Riel PL,. Modified disease activity scores that include twenty-eight-joint counts: development and validation in a prospective longitudinal study of patients with rheumatoid arthritis. Arthritis Rheum 1995; 38: 44-8.
26. Wells GA, Boers M, Shea B, Brooks PM, Simon LS, Strand CV, et al. Minimal disease activity for rheumatoid arthritis: a preliminary definition. J Rheumatol 2005; 32: 2016-24.
27. Deyo RA, Centor RM,. Assessing the responsiveness of functional scales to clinical change: an analogy to diagnostic test performance. J Chronic Dis 1986; 39: 897-906.
28. De Bruin AF, Diederiks JP, de Witte LP, Stevens FC, Philipsen H,. Assessing the responsiveness of a functional status measure: the Sickness Impact Profile versus the SIP68. J Clin Epidemiol 1997; 50: 529-40.
29. Hanley JA, McNeil BJ,. The meaning and use of the area under a receiver operating characteristic (ROC) curve. Radiology 1982; 143: 29-36.
30. Scott DL, Houssien DA,. Joint assessment in rheumatoid arthritis. Br J Rheumatol 1996; 35 Suppl: 14-8.
31. Felson DT, Anderson JJ, Boers M, Bombardier C, Chernoff M, Fried B, et al. The American College of Rheumatology preliminary core set of disease activity measures for rheumatoid arthritis clinical trials. Arthritis Rheum 1993; 36: 729-40.
32. Scott DL, Panayi GS, van Riel PL, Smolen J, van de Putte LB,. Disease activity in rheumatoid arthritis: preliminary report of the Consensus Study Group of the European Workshop for Rheumatology Research. Clin Exp Rheumatol 1992; 10: 521-5.
33. Aletaha D, Nell VP, Stamm T, Uffmann M, Pflugbeil S, Machold K, et al. Acute phase reactants add little to composite disease activity indices for rheumatoid arthritis: validation of a clinical activity score. Arthritis Res Ther 2005; 7: R796-806.
34. Leeb BF, Haindl PM, Maktari A, Nothnagl T, Rintelen B,. Disease activity score-28 values differ considerably depending on patient's pain perception and sex. J Rheumatol 2007; 34: 2382-7.
35. Radovits BJ, Fransen J, van Riel PL, Laan RF,. Influence of age and gender on the 28-joint Disease Activity Score (DAS28) in rheumatoid arthritis. Ann Rheum Dis 2008; 67: 1127-31.
36. Inoue E, Yamanaka H, Hara M, Tomatsu T, Kamatani N,. Comparison of Disease Activity Score (DAS)28-erythrocyte sedimentation rate and DAS28-C-reactive protein threshold values. Ann Rheum Dis 2007; 66: 407-9.
37. Aletaha D, Neogi T, Silman AJ, Funovits J, Felson DT, Bingham CO III, et al. 2010 rheumatoid arthritis classification criteria: an American College of Rheumatology/European League Against Rheumatism collaborative initiative. Ann Rheum Dis 2010; 69: 1580-8.
38. Fransen J, Visser K, van Dongen H, Huizinga T, van Riel PL, van der Heijde DM,. Validity of the disease activity score in undifferentiated arthritis. Arthritis Care Res (Hoboken) 2010; 62: 1392-8.
39. Felson DT, Smolen JS, Wells G, Zhang B, van Tuyl LH, Funovits J, et al. American College of Rheumatology/European League against Rheumatism provisional definition of remission in rheumatoid arthritis for clinical trials. Ann Rheum Dis 2011; 70: 404-13.